Journal of the Association of Nurses in AIDS Care
Volume 18, Issue 1 , Pages 36-47 , January 2007

Ritonavir-Boosted Protease Inhibitors: Impact of Ritonavir on Toxicities in Treatment-Experienced Patients

References 

  1. Acosta EP, Wu H, Hammer SM, Yu S, Kuritzkes DR, Walawander A, et al. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes. 2004;37:1358–1366
  2. Becker SL. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opinion on Investigational Drugs. 2003;12:401–412
  3. Boehringer Ingelheim Pharmaceuticals, Inc. (2005). Tipranavir [package insert]. Ridgefield, CT: Author.
  4. Bongiovanni M, Bini T, Chiesa E, Cicconi P, Adorni F, Monforte d’Arminio A. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: Immunovirological outcome and side effects. Antiviral Research. 2004;62:53–56
  5. Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EAM, Duncombe CJ, et al. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 2006. 2006;11:223–232
  6. Bristol-Myers Squibb. (2005). Atazanavir [package insert]. Princeton, NJ: Author.
  7. Brown T. T., Cole S. R., Li X., Kingsley L. A., Palella F. J., Jr., Riddler S. A., et al. (2004, February). Prevalence and incidence of pre-diabetes and diabetes in the Multicenter AIDS Cohort Study. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
  8. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Archives of Internal Medicine. 2005;165:1179–1184
  9. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999;13:213–224
  10. Churchill DR, Pym AS, Galpin S, Foxall R, Stainsby C, Clarke JR, et al. The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS Research and Human Retroviruses. 1999;15:1181–1189
  11. Clumeck N., Brun S., Sylte J., Isaacson J., Chen S., Lazzarin A., et al. (2001, February). Kaletra (ABT-378/r) and efavirenz: One-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients. Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Abstract No. 525.
  12. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clinical Infectious Diseases. 2003;36:1585–1592
  13. Correia MA. Drug biotransformation. In:  Katzung BG editors. Basic & clinical pharmacology. 9th ed.. New York: Lange Medical Books/McGraw-Hill, Medical Publishing Division; 2004;
  14. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs. 2003;63:769–802
  15. DeJesus E., Grinsztejn B., Rodriguez C., Nieto-Cisneros L., Coco J., Lazzarin A., et al. (2004, February). Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs. lopinavir/ritonavir (LPV/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS AI424-045. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Abstract No. 547.
  16. DeJesus E., LaMarca A., Sension M., Beltran C., Yeni P. (2003, February). The CONTEXT study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
  17. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial. Journal of Infectious Diseases. 2003;188:635–642
  18. Elston, R. C., Yates, P., Tisdale, M., Richards, N., White, S., DeJesus, E. (2004, July). GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype. Paper presented at the XV International AIDS Conference, Bangkok, Thailand. Abstract No. MoOrB1055. Retrieved January 14, 2005, from http://www.iasociety.org/ejias
  19. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annual Review of Pharmacology and Toxicology. 2000;40:649–674
  20. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d’Arminio Monforte A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?. Journal of Infectious Diseases. 2004;189:1056–1074
  21. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte , A El-Sadr WM, Reiss P, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine. 2003;349:1993–2003
  22. Gianotti N, Soria A, Galli L, Giudici B, Fusetti G, Lazzarin A, et al. Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. AIDS. 2004;18:821–823
  23. Gutierrez F, Padilla S, Navarro A, Masia M, Hernandez I, Ramos J, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. Journal of Acquired Immune Deficiency Syndromes. 2003;33:594–600
  24. Harley W., DeJesus E., Pistole M., Sension M., Garrett L., Nettler S., et al. (2001, February). A 24-week randomized, controlled, open-label evaluation of adherence and convenience of continuing indinavir versus switching to ritonavir/indinavir 400 mg/400 mg BID (The NICE Study). Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Abstract No. 334.
  25. Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005;19:145–152
  26. Katlama C., Arasteh K., Clotet B., Cooper D., Henry K., Lalezari J., et al. (2003, July). Enfuvirtide TORO studies: 48 week results confirm 24 week findings. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France. Abstract No. LB02.
  27. Katlama C., Berger D., Bellos N., Grinsztejn B., Haubrich R., Wilkin T., et al. (2005, February). Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. Abstract No. 164LB.
  28. Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine. 2003;4:94–100
  29. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18:641–649
  30. Lundgren J. D., Hill A., Fox Z., Clumeck N., Bruun J. N., Benetucci J., et al on behalf of the MaxCmin Trial Group. (2003, July). Hepatotoxicity of ritonavir-boosted indinavir (IDV/r 800/100 mg twice daily) and saquinavir (SAQ/r 1000/100 mg twice daily) in a phase IV, randomized, open-label, and multicentre trial in adult HIV-1 infection: the MaxCmin1 Trial. Paper presented at the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France.
  31. Martinez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldori F, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clinical Infectious Diseases. 2004;38:1017–1023
  32. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D Clinical Epidemiology Group from the French Hospital Database (2003). Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–2486
  33. McCallister S., Kohlbrenner V., Villacian J., Mukwaya G., Neubacher D., Mayers D. (2004, December). 24-week combined analysis for the TPV RESIST studies of 1483 treatment-experienced patients given either tipranavir/ritonavir (TPV/r) or an optimized standard of care regimen using 1 of 4 RTV-boosted comparator PIs (CPI/r). Paper presented at the HIV DART 2004, Montego Bay, Jamaica. Abstract No. 060.
  34. Neubacher D., Markowitz M., Slater L., Curry R., Mayers D., McCallister S. (2003, October). Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2). Paper presented at the 9th European AIDS Conference, Warsaw, Poland.
  35. Orrick JJ, Steinhart CR. Atazanavir. Annals of Pharmacotherapy. 2004;38:1664–1674
  36. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine. 1998;338:853–860
  37. Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Retrieved June 13, 2006, from http://aidsinfo.nih.gov/guidelines
  38. Parenti DM, Klouj A, Rice MM, Roberts AD, Liappis AP, Bisby N, et al. Evaluation of coronary artery calcification by electron beam computed tomography (EBCT) in HIV-infected men receiving prolonged protease inhibitor (PI) therapy. Antiviral Therapy. 2004;9:L65;Abstract No. 116
  39. Podzamczer D., Tressler R., Flexner C., Katlama C., Havlir D., Letendre S., et al. (2004, July). Higher doses of lopinavir/ritonavir (LPV/r) in highly treatment-experienced, HIV-infected patients: 48-week safety/efficacy evaluation. Poster presented at the 15th International AIDS Conference, Bangkok, Thailand. Poster TuPeB4555.
  40. Solas C, Basso S, Poizot-Martin I, Ravaux I, Gallais H, Gastaut JA, et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. Journal of Acquired Immune Deficiency Syndrome. 2002;29:374–377
  41. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277–2284
  42. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. Journal of Infection. 2005;50:331–337
  43. Vora S, Michon C, Junet C, Belavoine JF, Renold-Moynier C, Yerly S, et al. Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests. AIDS. 2000;14:2795–2797
  44. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. IDS. 1998;12:F167–F173
  45. Walmsley S., Benetucci J., Brutus A., Clumeck N., Dragsted U. B., Gazzard, B, et al. (2004, February). Lipid profiles of patients enrolled in the MaxCmin2 trial: A randomized, open-label, multicenter comparative trial evaluating the safety and efficacy of lopinavir/ritonavir (LPV/r; 400/100 MG bid) versus saquinavir/ritonavir (SAQ/r; 1000/100 MG bid). Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
  46. Weber R., Friis-Moller N., Sabin C., Reiss P., D’Arminio Monforte A., Dabis F., et al. (2005, February). HIV and non-HIV-related deaths and their relationship to immunodeficiency: The D:A:D Study. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
  47. Yeni P. Tipranavir: A protease inhibitor from a new class with distinct antiviral activity. Journal of Acquired Immune Deficiency Syndrome. 2003;34(Suppl. 1):S91–S94

PII: S1055-3290(06)00267-6

doi: 10.1016/j.jana.2006.11.003

Journal of the Association of Nurses in AIDS Care
Volume 18, Issue 1 , Pages 36-47 , January 2007

Article Tools